Showing results (271-280 of 284) with videos related to
Sort By:
Pageof 29
BMC Health Services Research|November 30, 2015
Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern UgandaG Abongomera, S Kiwuwa-Muyingo, P Revill, et al.HIV Medicine|July 16, 2003
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA studyE Florence, J Lundgren, C Dreezen, et al.HIV Medicine|February 26, 2015
Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialJ Grarup, C Rappoport, N W Engen, et al.AIDS Research and Human Retroviruses|August 1, 1998
Evaluation of different V3 peptides in an enzyme immunoassay for specific HIV type 1 group O antibody detectionP Ondoa, B Willems, K Fransen, et al.AIDS (London, England)|September 4, 1998
Improved detection of HIV-2 proviral DNA in dually seroreactive individuals by PCRK Ishikawa, K Fransen, K Ariyoshi, et al.BMC Infectious Diseases|November 5, 2015
Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrantsD Van Beckhoven, E Florence, J Ruelle, et al.The Journal of Infectious Diseases|February 13, 1999
Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995Y Guimard, M A Bwaka, R Colebunders, et al.HIV Medicine|February 26, 2015
Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialE Denning, S Sharma, M Smolskis, et al.AIDS (London, England)|July 1, 1996
Epidemiological and molecular characteristics of HIV infection in Gabon, 1986-1994E Delaporte, W Janssens, M Peeters, et al.Antiviral Therapy|June 22, 2001
Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in BelgiumK Van Vaerenbergh, L Debaisieux, N De Cabooter, et al.Pageof 29